22Sep3:14 pmEST

A Bigger Event Than Normal

Insmed, a small/mid-cap biotech focusing on rare diseases, is hosting an R&D day event on September 30th. After absorbing a common stock offering last May remarkably well, shares of the niche biotech firm spent all of this summer basing tightly sideways. 

Recently, INSM shot up on heavy buy volume (right-hand bottom pane of the daily chart, below). 

With price breaking out on heavy buy volume from multi-month tight range, combined with the GILD for IMMU fat premium buyout, I view INSM as one of several prime candidates to continue a possible biotech bonanza of M&A deals into the end of 2020. And with some uncertainty regarding the upcoming Election, those deals may get done sooner rather than later--After all, once we get even close to Thanksgiving we could easily see these deals get put on the shelf until a few weeks into 2021, and then who knows what will happen?

Moreover, with INSM being so specialized in biotech regarding rare diseases, the R&D day should count for more than usual as for the firm gaining exposure and analyst insights. 

Super Bowl LVI Sports Bettin... Jinx!

 
BackToTop
 

This website is intended for educational purposes only. | © 2025 MarketChess.com | All Rights Reserved | Website design by Saco Design | Superpowered by Site Avenger

mobile site | full site